What is the official website of Roche Austria ?

The official website of Roche Austria is https://www.roche.at/de/service/impressum.html.

What is Roche Austria's cybersecurity risk score?

Roche Austria has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Roche Austria experienced?

According to Rankiteo, Roche Austria currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Roche Austria been affected by any supply chain cyber incidents ?

According to Rankiteo, Roche Austria has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Roche Austria have SOC 2 Type 1 certification ?

According to Rankiteo, Roche Austria is not certified under SOC 2 Type 1.

Does Roche Austria have SOC 2 Type 2 certification ?

According to Rankiteo, Roche Austria does not hold a SOC 2 Type 2 certification.

Does Roche Austria comply with GDPR ?

According to Rankiteo, Roche Austria is not listed as GDPR compliant.

Does Roche Austria have PCI DSS certification ?

According to Rankiteo, Roche Austria does not currently maintain PCI DSS compliance.

Does Roche Austria comply with HIPAA ?

According to Rankiteo, Roche Austria is not compliant with HIPAA regulations.

Does Roche Austria have ISO 27001 certification ?

According to Rankiteo,Roche Austria is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Roche Austria operate in ?

Roche Austria operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Roche Austria have ?

Roche Austria employs approximately None employees people worldwide.

Does Roche Austria own any subsidiaries ?

Roche Austria presently has no subsidiaries across any sectors.

How many LinkedIn followers does Roche Austria have ?

Roche Austria's official LinkedIn profile has approximately 7,725 followers.

What is the NAICS classification code for Roche Austria ?

Roche Austria is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Roche Austria have a Crunchbase profile ?

No, Roche Austria does not have a profile on Crunchbase.

Does Roche Austria have a LinkedIn profile ?

Yes, Roche Austria maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/roche-austria.

How many cybersecurity incidents has Roche Austria experienced ?

As of September 15, 2026, Rankiteo reports that Roche Austria has not experienced any cybersecurity incidents.

How many peer or competitor companies does Roche Austria have ?

Roche Austria has an estimated 5,761 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Roche Austria

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Roche Austria Vendor Cyber Rating & Cyber Score

roche.at

Add Your Compliance Badge

Doing now what patients need next. Roche Austria ist neben Roche Diagnostics und Roche Diabetes Care eine der drei eigenständigen Roche Vertriebsgesellschaften in Österreich (Standort Wien). *** Bei Roche leisten 94.000 Menschen in 100 Ländern Pionierarbeit im Gesundheitswesen. Gemeinsam haben wir uns zu einem weltweit führenden, forschungsorientierten Healthcare-Konzern entwickelt. Unser Erfolg baut auf Innovation, Neugier und Vielfalt. Seit Gründung im Jahr 1896 erforscht Roche bessere Wege, um Krankheiten zu verhindern, zu erkennen und zu behandeln und leistet einen nachhaltigen Beitrag zur gesellschaftlichen Entwicklung. Auf der Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation stehen aktuell 30 von Roche

Roche Austria

Roche Austria CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Roche Austria Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Roche Austria

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Roche Austria in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Roche Austria in 2026.

Incident Types Roche Austria vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Roche Austria in 2026.

Incident History - Roche Austria (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Roche Austria Subsidiaries

Roche Austria

Pharmaceutical Manufacturing

Website: https://www.roche.at/de/service/impressum.html

Company Size: 201-500 employees

GenentechBiotechnology Research

Genentech MedicalBiotechnology Research

Roche Middle EastBiotechnology Research

Roche Diabetes Care FranceFabrication d’équipements médicaux

Roche Diagnostics Asia PacificBiotechnology Research

Roche MéxicoPharmaceutical Manufacturing

Loading…

Roche Austria Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

Roche Austria CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-91201

SUMMARY

DocsGPT through 0.20.0 posts OAuth connector session tokens to a wildcard target origin in the callback-status endpoint without validating sender origin. Attackers can obtain session tokens and provider account emails by acting as window.opener during OAuth authorization, then use tokens to disconnect victims' cloud storage connectors.

Published

Date2026-09-14

Updated

Date2026-09-14

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:N/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

2.8

REFERENCES

CVE-2026-91200

SUMMARY

DevSpace through 6.3.21 fails to reject parent-directory segments in tar entry names from the in-pod sync stream. Attackers operating a malicious container can stream tar entries with traversal sequences to write arbitrary files on the developer workstation, enabling code execution.

Published

Date2026-09-14

Updated

Date2026-09-14

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-91199

SUMMARY

Refly through 1.1.0 contains a server-side request forgery vulnerability in the POST /v1/misc/scrape endpoint that fetches caller-supplied URLs without validating the scheme, host, or resolved address. Authenticated attackers can make the backend issue requests to loopback, private, and link-local addresses including cloud metadata services to read page titles and descriptions of internal resources.

Published

Date2026-09-14

Updated

Date2026-09-14

RISK INFORMATION (Score: 5)

cvss3

Base Score: 5.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:N/A:N

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:L/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.1

REFERENCES

CVE-2026-91198

SUMMARY

GrowthBook through 5.0.1 returns unredacted fact table definitions including raw warehouse SQL in payloads served by unauthenticated public report and experiment endpoints. Attackers with knowledge of a publicly shared report or experiment identifier can read internal data warehouse query text, schema, table names, filter values and datasource identifiers.

Published

Date2026-09-14

Updated

Date2026-09-14

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-91197

SUMMARY

Flowable flowable-engine through 8.0.0 contains an XML external entity injection vulnerability in ProcessDiagramLayoutFactory.parseXml() that fails to disable external entity resolution when parsing deployed BPMN resources. Attackers with process deployment privileges can embed DOCTYPE declarations with external entities in BPMN files to read arbitrary local files or trigger requests to internal network endpoints when diagram layout is computed.

Published

Date2026-09-14

Updated

Date2026-09-14

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Roche Austria Vendor Cyber Rating & Cyber Score

Roche Austria A.I CyberSecurity Scoring

Roche Austria CyberSecurity News & History

Roche Austria Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Roche Austria

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Roche Austria vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Roche Austria (X = Date, Y = Severity)

Roche Austria Subsidiaries

Roche Austria

Roche Austria Similar Companies

MENARINI Group

Alembic Pharmaceuticals Limited

Novartis

EMS

Eli Lilly and Company

Alkem Laboratories Ltd.

UCB

Catalent

PT Kalbe Farma, Tbk

Roche Austria CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Roche Austria CyberSecurity News & History

Roche Austria Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Roche Austria

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Roche Austria vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Roche Austria (X = Date, Y = Severity)

Roche Austria Subsidiaries

Roche Austria

Roche Austria Similar Companies

MENARINI Group

Alembic Pharmaceuticals Limited

Novartis

EMS

Eli Lilly and Company

Alkem Laboratories Ltd.

UCB

Catalent

PT Kalbe Farma, Tbk

Roche Austria CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo